Na Pɛptid Infɔmeshɔn 
Me 1, 2025, ɛn dis
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Polypeptide Purity Kontrol ɛn Vɛrifikɛshɔn Tɛknikal Sistɛm
Cocerpeptides.com de gi pεptida dεm wit klin we pas 99%. Cocer Peptides de ajɔst prɛsis kɔntrol ɛn sayɛns verifyeshɔn fɔ di polypeptide puriti bay we i de intagret advans teknɔlɔji dɛn ɛn wan ful-prɔses kwaliti kɔntrol sistɛm: Insay di sεntesis stej, dɛn de yuz ɔtomatik sɔlid-fεz pεptida sεntez (SPPS) fכ akכrd asemble amino asid sikεns dεm. Wan gradient purifyeshɔn strateji we de frɔm midul-prɛshɔn likwid kromatografi (MPLC) to prɛparativ ay-pɔfɔmɛnshɔn likwid kromatografi (Prep-HPLC) de yuz, we de ɔptimayz mobayl faz kɔmpɔzishɔn ɛn elushɔn kɔndishɔn dɛn bays pan di fizikokɛmikɛl prɔpati dɛn fɔ di target peptide (haydrofobisiti, chaj distribyushɔn, ɛn ɔda tin dɛn) fɔ pul di impyuriti dɛn fayn fayn wan. Fכ puriti dεtekshכn, rivεs-fεz hεy-pεrformεns likwid kromatografi (RP-HPLC) de sav as di kכr tεknik, we de sεparayt kכmכpכnt dεm tru di distribushכn difrεns fכ mכlikul dεm bitwin di steshכnal fεz (haydrofכbik pak) εn di mobayl fεz (pכlar sכlvεnt). Purity de ditarmin via ritɛnshɔn tɛm maching ɛn pik eria nɔmalizeshɔn. Na da tɛm de, dɛn kin kɔba ilɛktrɔsprɛy ayɔnizashɔn mas spɛktrometri (ESI-MS) fɔ prɛsishɔn fɔ verify di mɔlikul wet ɛn kɔmpɔzishɔn tru mas-to-chaj rɛtɛshɔn (m/z) analisis, we de pul strɔkchɔral itɛrojɛnik impyuriti. Kwaliti manejmɛnt kɔba di ɔl chen frɔm raw matirial akseptɛns, sɛntesis prɔses monitarin to finish prodak rilis. Dɛn kin kɔnstrɔk wan kɔntinyu kwaliti finga prɛnt bay we dɛn de yuz mɔlti-dimɛnshɔnal indikɛtɔ dɛn (HPLC klin, MS mɔlikul wet, sɔlvɛnt rɛsɛdyu, ɛn ɔda tin dɛn), ɛn dɛn kin ajɔst batch data traysabiliti tru wan lɛbɔraytri infɔmeshɔn mɛnejɛmɛnt sistɛm (LIMS), we de mek shɔ se ɛni batch mit di prɛspɛsifikɛd klin standad dɛn. Dis sistεm de gi wan rilibul tεknikal gεranti fכ pripia hεy-pכriti polipεptida dεm tru di כrganik intagrεshכn fכ prכsεs optimayzεshכn, mכlti-dimεnshכnal dεtekshכn, εn ful-prכsεs kwaliti kכntrכl.
Kɔnsɛpt fɔ Ay-Pɔfɔmɛnshɔn Likwid Kromatografi (HPLC) ɛn Mas Spɛktrometri (MS) .
High-performance liquid chromatography (HPLC) na wan separeshכn tεknכlכji we Cocer Peptides de yuz bכku fכ pεptida purifyushכn. We dɛn de drɛb am bay wan ay-prɛshɔn pɔmp, di mobayl faz de kɛr sɛmpul dɛn tru wan kromatografik kɔlɔm we pak wit wan spɛshal steshɔnari faz, we de ajɔst separeshɔn bays pan difrɛns dɛn na di distribyushɔn kɔfishin dɛn fɔ di kɔmpɔnɛnt dɛn bitwin di tu faz dɛn. i fכm hכy separeshכn efyushכn, fast analisis spid, εn strכng dεtekshכn sεnsitiviti, we de mek i ebul fכ kכpכt prεsis difrεns bitwin tכgεt pεptida dεm εn impyuriti lεk sikεns analכg כ dilit pεpti dεm.
Mas spεktrכmetri (MS) na wan analitik mεtכd we de kכnvכlt pεptida mכlikul dεm to gas-fεz ayכn tru ayכnayzεshכn tεknכlכji εn separet/dεtekt ayכn bays pan dεn mas-to-chaj rεshכ (m/z). i kin akכrd ditarmin di mכlikul wet fכ di pεptida dεm εn infεr amino asid sikεns dεm tru fragmεnt ayכn infכmeshכn, we de sav as ki tεknכlכji fכ vεrifik pεptida strכkchכral kכrekt. Di kɔmbaynshɔn fɔ dɛn tu tɛknik ya de alaw Cocer Peptides fɔ establish wan kɔmplit kwaliti kɔntrol sistɛm frɔm ɔl tu di puriti separeshɔn ɛn strɔkchɔral kɔnfɔmeshɔn pɔsibul. di tu mεtכd dεm na hεy-prεsishכn pεptida dεtekshכn tεknכlכji dεm we sayɛnsli de sho di klin εn kכmכshכn fכ pεptida dεm we dεn כda frכm cocerpeptides.com.
Cocer Peptides de komit fɔ translet di kɔt-ɛj analitik teknɔlɔji dɛn to tanjibul kwaliti ɛshyurishɔn. Wi pεptida sεntesis labכtכri dεm gεt hεy-rεsכlushכn mas spεktrכmita dεm εn כltra-hay-pεrformεns likwid kromatografi sistεm dεm. Tru rial-taym ditekshɔn ɛn data kɔmpiashɔn fɔ sampul dɛn na ɛni prodakshɔn stej, wi kɔntinyu fɔ ɔptimayz sɛntesis prɔses fɔ mek shɔ se ɛvri peptide prodak de delivr to kɔstɔma dɛn wit ɛksɛpshɔn klin.
Di Lɛvɛl dɛn we dɛn kin yuz fɔ mek di Pɛptid Klin
Cocer Peptides de gi כnli di hεyest-purity peptides (purity ≥99%) fכ risεch εn divεlכpmεnt. di minim rεkomεnd pεptida puriti lεvεl fכ spεsifi k aplikεshכn dεm dipכnt pan di aplikεshכn:
• insay bayokemכnik risεch, pεptida dεm we dεn yuz fכ εnzym aktiviti analisis tipikli nid ≥85% puriti.
• insay dכg divεlכpmεnt, pεpti dεm fכ prεklinik trial dεm fכ mit >98% hεy-puriti standad fכ mek sכh se bayolojikal aktiviti εn sef.
• fכ diagnostik aplikεshכn dεm (εgz., antijen pεptida dεm insay immunoassays), rεkomεndεd puriti na 90%-95% fכ gεran ditekshכn spεsifisiti εn sεnsitiviti.
Cocer Peptides gɛt kɔnfidɛns pan di kwaliti fɔ ɔl wi prɔdak dɛm, i de impruv strikt kwaliti monitarin na ɛvri stej fɔ peptide sɛntesis—frɔm krud peptide purifyeshɔn to fayn prodak rilis. Tru multi-step purification ɛn verification prɔses, wi de mek shɔ se ɛni batch mit ɔ pas di puriti rikwaymɛnt fɔ spɛshal aplikeshɔn dɛn. εgzampl dεm fכ akseptabl minim puriti lεvεl dεm na dεn wan ya:
High Purity (>95%) we gɛt di sik.
• SMƆL TƆK: Polipɛptid drɔg risach ɛn prodakshɔn
• SMƆL TƆK: Fɔ pripia di tritmɛnt drɔgs dɛn we dɛn dɔn tɔk bɔt
• Raw matirial fɔ bayolojikal diagnostik rijen (ɛgz., ELISA, immunoassay kit) .
• Divεlכpmεnt כf polipεptida vaksin (tεrapi/prεvεntiv) .
• Prεparashכn fכ tכgεt pεpti dεm fכ antibodi-drug kכnjugεt (ADC) dεm .
• Polipεptida rijen fכ layf sayns risach (εgz., rεsεpכta agonist/antagonist) .
• Risach pan tכgεt pεptida modifyushכn fכ jin tεrapi vεktכr dεm
• Divεlכpmεnt fכ polipεptida antibaytik/antimaykrobial pεptida dεm
• Prεparashכn fכ di polipεptida כmon analכg dεm (εgz., insulin analכg dεm) .
• SMƆL TƆK: Rifrɛns standad fɔ bayomak ditekshɔn
• Risach pan sɛl kɔlchɔ aditiv dɛm
• sεntetik pεpti dεm fכ protin strכkchכ analisis εn fכnshכnal stכdi dεm
Modaret Puriti (>85%) we de mek pɔsin klin.
• SMƆL TƆK: Ɛli-stej aktiviti skrinin insay polipɛptida drɔg risach
• Pεptid aditiv fכ industrial εnzym dεm
• Signal pεptida raw mεtirial dεm
• SMƆL TƆK: Sɔfayz modifyeshɔn fɔ bayɔmatirial dɛn (ɛgz., mɛdikal kateshɔn, tisu injinɛri skɔf) .
• SMƆL TƆK: Prɛparashɔn fɔ agrikalchɔral antimaykrobial peptida dɛm
• SMƆL TƆK: Risach bɔt sɛl adheshon
• Raw matirial fɔ polipɛptida sɔfaynt/ditajɛn
• Polypeptide reagents fכ prεliminεri mεkanikal risεch insay sayntis stכdi dεm
Lɔwa Puriti (>70%) .
• SMƆL TƆK: Prɛliminari strɔkchɔ-aktiviti rilayshɔn (SAR) stɔdi
• Initial vεrifikεshכn fכ di protin binding
• SMƆL TƆK: Praymari saytotoksisiti skrinin
• SMƆL TƆK: Ha-throughput skrinin fɔ polypeptide drɔg lid kɔmpawnd dɛn
di hכy-puriti polipεptida dεm fayn fכ sεnariכ dεm we nid strikt kכlכ. di ultra-high-purity pεpti dεm we Cocer Peptides de gi kin mit εn pas כl di prεspεsifiket puriti standad dεm.
